Scinus Cell Expansion BV, a RegMed XB partner, has made the next step in bringing solutions to patients. Prometheus at KU Leuven, Belgium, installed a novel bioreactor from Scinus Cell Expansion B.V.

Selma Kaffka genaamd Dengler, Clémence Odille, Mudit Mishra, Niels van der Kaaij, Pieter Doevensdans, Joost Sluijter and Saskia de Jager from the University Medical Center Utrecht published the paper:

The Utrecht-based company TargED Biopharmaceuticals received the first start-up funding from the FIRST fund, founded by the DCVA, RegMed XB and RVO. With the support of this new investment, the company can conduct follow-up research with their compound (Microlysis) that dissolves blood clots. The potential effect of this drug in strokes was discovered at UMC Utrecht.